Photo credit: Getty Images
AI technology that could revolutionize diabetic eyecare.
May 8, 2024
AEYE Health, a provider of artificial intelligence retinal imaging and diagnostics, received FDA clearance for a fully autonomous AI technology that diagnoses referable diabetic retinopathy from retinal images obtained by a handheld camera, according to a press release issued by AEYE Health on PR Newswire.
“Combining a fully autonomous AI with a portable handheld device introduces a new and affordable screening solution to address the leading cause of blindness in the working age. The portable solution is especially suited for point-of-care screening, enabling screenings wherever patients are located – whether in clinic or at-home,” AYEYE Health stated in the press release.
AEYE Diagnostic Screening technology (AEYE-DS) is already cleared by the FDA and commercially available with a tabletop imaging device, and will now become the first and only AI solution to allow autonomous screening anywhere using the Optomed Aurora portable handheld device. AEYE-DS is also the only solution that screens patients using just one image per eye with over 99 percent “imageability,” according to the company.
Other Articles to Explore
This new FDA clearance is based on two large-scale prospective phase-III studies, in which AEYE-DS demonstrated best-in-class efficacy and imageability. Diagnostic sensitivity was in the range of 92-93 percent and specificity was in the range of 89-94 percent. In both studies, over 99 percent of patients received a diagnostic result. The AI produced its diagnostic results using only a single image from each eye, rarely requiring dilation.
“This is the ‘holy grail’ of eye screening – fully autonomous AI, using either portable or tabletop retinal cameras and a procedure that takes a minute to perform, alongside the best-in-class diagnostic efficacy,” says Zack Dvey-Aharon, Ph.D., Co-Founder & CEO of AEYE Health. “In the coming years our fully-autonomous screening technology will become standard across points of care in the U.S. We believe this innovation will prevent the blindness of millions of people in the U.S. and around the world.”
Dr. Dvey-Aharon adds: “AEYE keeps working to expand the boundaries of diagnostic screening beyond diabetic retinopathy. Our science is evidently the strongest in this space and we’re proud to make such unbelievable impact.”
Tsontcho Ianchulev, MD, Professor of Ophthalmology at New York Eye and Ear of Mount Sinai and Board member of AEYE Health, says, “This is perhaps the most exciting FDA clearance I’ve seen in the recent years. Such meaningful and impactful innovation – not only on the technology and clinical care front, but also for population health. A simple click without dilation right when you visit your primary care doctor, at the pharmacy or even at home, can instantly inform you about diabetic retinopathy. This can streamline care, reduce patient burden, and ultimately ensure exponential access to essential sight-saving service. Earlier systems have struggled because of efficacy, throughput, imageability, portability and need for dilation, but we see a major leap forward technologically with this holy grail system that really has it all.”
